{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:48:54Z","timestamp":1787071734726,"version":"build-2736575974"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate factors contributing to retreatment after antivascular endothelial growth factor (anti-VEGF) therapy in patients with retinopathy of prematurity (ROP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>All relevant publications released up to November 2022 from PubMed, Google Scholar, and Scopus were evaluated. An Excel checklist was developed for data extraction, including author names, publication year, sample size, mean gestational age (GA), birth weight (BW), zone of ROP, total and zone-specific retreatment incidence, and the percentage of aggressive posterior ROP eyes. The primary outcome was the incidence of retreatment (IR). The mixed methods appraisal tool was used to assess the quality of the papers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The total IR was 19% (95% confidence interval (CI): 15%\u201323%). Among children treated with anti-VEGF agents, the highest IR occurred with intravitreal ranibizumab (IVR, 0.25 mg) (27%, 95% CI: 19%\u201335%) and intravitreal aflibercept (IVA, 0.4 mg) (27%, 95% CI: 6%\u201347%), followed by intravitreal conbercept (IVC, 0.25 mg) (16%, 95% CI: 13%\u201320%). The lowest IR was observed in children treated with intravitreal bevacizumab (IVB, 0.625 mg) (11%, 95% CI: 7%\u201314%). In the IVR group, the chance of retreatment increased by 7% for every 1-week increase in GA and 5% for every 100 g of BW. In general, the IR was significantly higher in Zone I ROP in comparison with Zone II. For patients with Zone I ROP who received IVR, the IR was 0.36 (95% CI: 0.09\u20130.62), while for those who underwent IVB, it was 0.06 (95% CI: 0.01\u20130.11). The difference between the two groups was statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03). The IR for retreatment in patients with Zone II ROP was 0.13 (95% CI: 0.01\u20130.26) for IVR and 0.00 (95% CI: 0.00\u20130.01) for the IVB subgroup (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>While anti-VEGF therapy is effective for ROP treatment, there are significant differences in IR among different agents. IVB treatment appears to yield the most consistent results compared to other agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joco.joco_17_25","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:00:28Z","timestamp":1763132428000},"page":"20-30","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Investigating Predictors of Retreatment following Initial Antivascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis"],"prefix":"10.4103","volume":"37","author":[{"given":"Samira","family":"Chaibakhsh","sequence":"first","affiliation":[{"name":"Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Abri Aghdam","sequence":"additional","affiliation":[{"name":"Eye Research Center, Eye Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Babaei","sequence":"additional","affiliation":[{"name":"Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hemmati","sequence":"additional","affiliation":[{"name":"Eye Research Center, Eye Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengameh","family":"Kasraei","sequence":"additional","affiliation":[{"name":"Eye Research Center, Eye Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aghajani","sequence":"additional","affiliation":[{"name":"Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"R1-20251117","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.preteyeres.2017.09.002","article-title":"Pathophysiology, screening and treatment of ROP:A multi-disciplinary perspective","volume":"62","author":"Chan-Ling","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R2-20251117","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","article-title":"Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)","volume":"18","author":"Li","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"R3-20251117","doi-asserted-by":"crossref","first-page":"884608","DOI":"10.3389\/fmed.2022.884608","article-title":"Intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity:A systematic review and meta-analysis","volume":"9","author":"Taher","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R4-20251117","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"key":"R5-20251117","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-20251117","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","article-title":"Comparison in retreatments between bevacizumab and ranibizumab intravitreal injections for retinopathy of prematurity:A multicenter study","volume":"130","author":"Patel","year":"2023","journal-title":"Ophthalmology"},{"key":"R7-20251117","doi-asserted-by":"crossref","first-page":"1202927","DOI":"10.3389\/fped.2023.1202927","article-title":"Ranibizumab for the treatment of retinopathy of prematurity:Systematic review and meta-analysis","volume":"11","author":"Alva","year":"2023","journal-title":"Front Pediatr"},{"key":"R8-20251117","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13052-023-01543-3","article-title":"The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity:A systematic review and meta-analysis","volume":"49","author":"Chen","year":"2023","journal-title":"Ital J Pediatr"},{"key":"R9-20251117","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00417-023-06224-9","article-title":"Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity:A network meta-analysis of randomised controlled trials","volume":"262","author":"Zhou","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R10-20251117","first-page":"585","article-title":"Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity:A network meta-analysis","volume":"69","author":"Ortiz-Seller","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"R11-20251117","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/EFI-180221","article-title":"The mixed methods appraisal tool (MMAT) version 2018 for information professionals and researchers","volume":"34","author":"Hong","year":"2018","journal-title":"Educ Inform"},{"key":"R12-20251117","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R13-20251117","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4103\/tjo.tjo_69_18","article-title":"Bevacizumab or laser for aggressive posterior retinopathy of prematurity","volume":"8","author":"Blair","year":"2018","journal-title":"Taiwan J Ophthalmol"},{"key":"R14-20251117","doi-asserted-by":"crossref","first-page":"e0223972","DOI":"10.1371\/journal.pone.0223972","article-title":"Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment","volume":"14","author":"Chang","year":"2019","journal-title":"PLoS One"},{"key":"R15-20251117","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity:Comparison between ranibizumab and bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"R16-20251117","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/eye.2014.172","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity:2-year outcomes","volume":"28","author":"Chen","year":"2014","journal-title":"Eye (Lond)"},{"key":"R17-20251117","doi-asserted-by":"crossref","first-page":"4565216","DOI":"10.1155\/2018\/4565216","article-title":"Refractive and biometric outcomes in patients with retinopathy of prematurity treated with intravitreal injection of ranibizumab as compared with bevacizumab:A clinical study of correction at three years of age","volume":"2018","author":"Chen","year":"2018","journal-title":"J Ophthalmol"},{"key":"R18-20251117","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s10792-019-01088-7","article-title":"Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP","volume":"39","author":"Ekinci","year":"2019","journal-title":"Int Ophthalmol"},{"key":"R19-20251117","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"R20-20251117","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcjo.2020.05.017","article-title":"Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity:Can they support rescue laser photocoagulation to the avascular retina","volume":"55","author":"Gonzalez","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"R21-20251117","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5935\/0004-2749.20150079","article-title":"Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity","volume":"78","author":"Gunay","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"R22-20251117","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res"},{"key":"R23-20251117","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1111\/aos.13004","article-title":"Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity:A case series with paired-eye comparison","volume":"96","author":"Han","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"R24-20251117","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity:A 5-Year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"R25-20251117","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"J AAPOS"},{"key":"R26-20251117","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/IAE.0b013e3181ca1457","article-title":"Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin)","volume":"30","author":"Dorta","year":"2010","journal-title":"Retina"},{"key":"R27-20251117","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children","volume":"42","author":"Kabata\u015f","year":"2017","journal-title":"Curr Eye Res"},{"key":"R28-20251117","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7196\/SAMJ.2017.v107i3.11080","article-title":"The efficacy of intravitreal antivascular endothelial growth factor as primary treatment of retinopathy of prematurity:Experience from a tertiary hospital","volume":"107","author":"Kana","year":"2017","journal-title":"S Afr Med J"},{"key":"R29-20251117","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular endothelial growth factor treatment of retinopathy of prematurity:Efficacy, safety, and anatomical outcomes","volume":"32","author":"Kang","year":"2018","journal-title":"Korean J Ophthalmol"},{"key":"R30-20251117","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/jovr.jovr_198_16","article-title":"Efficacy of intravitreal bevacizumab for the treatment of zone i type 1 retinopathy of prematurity","volume":"13","author":"Karkhaneh","year":"2018","journal-title":"J Ophthalmic Vis Res"},{"key":"R31-20251117","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/aos.13008","article-title":"Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity","volume":"94","author":"Karkhaneh","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"R32-20251117","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000489023","article-title":"Comparison of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity affecting zone 1","volume":"240","author":"Kimyon","year":"2018","journal-title":"Ophthalmologica"},{"key":"R33-20251117","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapY","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"R34-20251117","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"R35-20251117","doi-asserted-by":"crossref","first-page":"102582","DOI":"10.1155\/2015\/102582","article-title":"Outcomes and prognostic factors of intravitreal bevacizumab monotherapy in Zone I Stage 3+and aggressive posterior retinopathy of prematurity","volume":"2015","author":"Nicoar\u0103","year":"2015","journal-title":"J Ophthalmol"},{"key":"R36-20251117","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","article-title":"Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity","volume":"2","author":"Roohipoor","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R37-20251117","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4172\/2155-9570.1000113","article-title":"Intravitreal bevacizumab injection as a primary therapy for threshold disease (rop) in al qassim region","volume":"1","author":"Salman","year":"2010","journal-title":"J Clinic Experiment Ophthalmol"},{"key":"R38-20251117","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5935\/0004-2749.20170009","article-title":"The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity","volume":"80","author":"Sukgen","year":"2017","journal-title":"Arq Bras Oftalmol"},{"key":"R39-20251117","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","article-title":"Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity \u201327 month follow-up results from Turkey","volume":"253","author":"Yetik","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R40-20251117","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"S\u00fcren","year":"2022","journal-title":"Int Ophthalmol"},{"key":"R41-20251117","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00417-021-05137-9","article-title":"Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity","volume":"259","author":"Murakami","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R42-20251117","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40942-021-00334-4","article-title":"Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity","volume":"7","author":"Riazi-Esfahani","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R43-20251117","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1159\/000500310","article-title":"Intravitreal ranibizumab injection for the treatment of retinopathy of prematurity","volume":"28","author":"Aldebasi","year":"2019","journal-title":"Med Princ Pract"},{"key":"R44-20251117","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.oret.2017.11.012","article-title":"Analysis of the recurrence of plus disease after intravitreal ranibizumab as a primary monotherapy for severe retinopathy of prematurity","volume":"2","author":"Ar\u00e1mbulo","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R45-20251117","doi-asserted-by":"crossref","first-page":"2985161","DOI":"10.1155\/2019\/2985161","article-title":"Serum vascular endothelial growth factor levels before and after intravitreous ranibizumab injection for retinopathy of prematurity","volume":"2019","author":"Chen","year":"2019","journal-title":"J Ophthalmol"},{"key":"R46-20251117","doi-asserted-by":"crossref","first-page":"e1004","DOI":"10.1111\/aos.14460","article-title":"Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity","volume":"98","author":"Cheng","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"R47-20251117","doi-asserted-by":"crossref","first-page":"5078565","DOI":"10.1155\/2017\/5078565","article-title":"Recurrence of retinopathy of prematurity in zone II Stage 3+after ranibizumab treatment:A retrospective study","volume":"2017","author":"Hu","year":"2017","journal-title":"J Ophthalmol"},{"key":"R48-20251117","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity:Anatomic outcomes and influencing factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"R49-20251117","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity","volume":"38","author":"Jin","year":"2018","journal-title":"Retina"},{"key":"R50-20251117","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy:Timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R51-20251117","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12886-019-1067-4","article-title":"Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age:A retrospective case series study","volume":"19","author":"Lyu","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"R52-20251117","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.18240\/ijo.2019.07.15","article-title":"The process of retinal vascularization in retinopathy of prematurity after ranibizumab treatment in China","volume":"12","author":"Meng","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"R53-20251117","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000449530","article-title":"The process of retinal vascularization after Anti-VEGF treatment in retinopathy of prematurity:A comparison study between ranibizumab and bevacizumab","volume":"236","author":"Alyama\u00e7Sukgen","year":"2016","journal-title":"Ophthalmologica"},{"key":"R54-20251117","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R55-20251117","first-page":"641","article-title":"Effect of anti-VEGF treatment on retinopathy of prematurity in Zone II Stage 3()","volume":"11","author":"Yang","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"R56-20251117","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3109\/02713683.2015.1084643","article-title":"Effects of Intravitreal ranibizumab in the treatment of retinopathy of prematurity in Chinese infants","volume":"41","author":"Yi","year":"2016","journal-title":"Curr Eye Res"},{"key":"R57-20251117","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina"},{"key":"R58-20251117","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/bjophthalmol-2020-318026","article-title":"Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity:A multicentral prospective randomised controlled trial","volume":"106","author":"Wu","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R59-20251117","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the rainbow trial","volume":"6","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"R60-20251117","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1097\/IAE.0000000000002754","article-title":"Anatomical and functional results of intravitreal aflibercept monotherapy for type 1 retinopathy of prematurity:One-Year outcomes","volume":"40","author":"Chen","year":"2020","journal-title":"Retina"},{"key":"R61-20251117","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res"},{"key":"R62-20251117","doi-asserted-by":"crossref","first-page":"884","DOI":"10.4103\/ijo.IJO_708_18","article-title":"Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity","volume":"67","author":"Vedantham","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R63-20251117","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","article-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","volume":"123","author":"Toy","year":"2016","journal-title":"Ophthalmology"},{"key":"R64-20251117","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/IAE.0000000000001996","article-title":"Fluorescein angiographic evaluation of peripheral retinal vasculature after primary intravitreal ranibizumab for retinopathy of prematurity","volume":"39","author":"Harper","year":"2019","journal-title":"Retina"},{"key":"R65-20251117","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.survophthal.2020.12.002","article-title":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity:A meta-analysis of 3,701 eyes","volume":"66","author":"Popovic","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"R66-20251117","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s10792-022-02480-6","article-title":"Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity:A systematic review","volume":"43","author":"Tsiropoulos","year":"2023","journal-title":"Int Ophthalmol"},{"key":"R67-20251117","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3928\/23258160-20211124-01","article-title":"Aflibercept for retinopathy of prematurity:A systematic review and meta-analysis","volume":"52","author":"Chen","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R68-20251117","doi-asserted-by":"crossref","first-page":"676","DOI":"10.17305\/bb.2023.9829","article-title":"Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity:A network meta-analysis","volume":"24","author":"Xu","year":"2023","journal-title":"Biomol Biomed"},{"key":"R69-20251117","doi-asserted-by":"crossref","first-page":"890","DOI":"10.4103\/ijo.IJO_1538_22","article-title":"Study to evaluate the relation between weight gain in infants and occurrence of retinopathy of prematurity","volume":"71","author":"Sethi","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R70-20251117","doi-asserted-by":"crossref","first-page":"e2135879","DOI":"10.1001\/jamanetworkopen.2021.35879","article-title":"The use of postnatal weight gain algorithms to predict severe or type 1 retinopathy of prematurity:A systematic review and meta-analysis","volume":"4","author":"Athikarisamy","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R71-20251117","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"ophthalmology"}],"container-title":["Journal of Current Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_17_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:52:49Z","timestamp":1787068369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_17_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/joco.joco_17_25","relation":{},"ISSN":["2452-2325"],"issn-type":[{"value":"2452-2325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2025-01-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}